Arca Biopharma | ABIO - Operating Expenses


Arca Biopharma reported $36.43M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 5.69B 6B Sep/2026
Arca Biopharma USD 36.43M 2M Mar/2026
Biogen USD 2.32B 663.6M Sep/2026
Brainstorm Cell Therapeutics USD 2.05M 198K Mar/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Cipla INR 63.61B 1.3B Sep/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.44M 246K Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 214.64M 6.85M Sep/2026
Daiichi Sankyo JPY 483.8B 5.85B Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Grifols EUR 1.99B 217.4M Dec/2025
Laboratory Of America USD 3.39B 117.6M Sep/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Otsuka Holdings JPY 567.81B 6.18B Sep/2026
Pfizer USD 89B 3.81B Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026